Trypanosoma cruzi: analysis of two different strains Check for after piplartine treatment

Author(s)

Licursi Vieira, Gabriela Alves ^[1] ; Alves da Silva, Marco Tulio ^[2] ; Regasini, Luis Octavio ^[3] ; Cotinguiba, Fernando ^{[1, 4]} ; Laure, Helen Julie ^[5] ; Rosa, Jose Cesar ^[5] ; Furlan, Maysa ^[1] ; Barretto Cicarelli, Regina Maria ^[6]

Affiliation

^[1] Univ Estadual Paulista UNESP, Inst Quim, Araraquara, SP - Brazil

^[2] Univ Sao Paulo, Inst Fis Sao Carlos, Sao Carlos, SP - Brazil

^[3] Univ Estadual Paulista UNESP, Inst Biociencias Letras & Ciencias Exatas, Sao Jose Do Rio Preto, SP - Brazil

^[4] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, IPPN, Rio de Janeiro, RJ - Brazil

^[5] Univ Sao Paulo, Fac Med Ribeirao Preto, Ctr Quim Prot, Ribeirao Preto, SP - Brazil

^[6] Univ Estadual Paulista UNESP, Fac Ciencias Farmaceut, Araraquara, SP - Brazil

• Document type: Journal article
• Source: Brazilian Journal of Infectious Diseases; v. 22, n. 3, p. 208-218, MAY-JUN 2018.
• Web of Science Citations: 1

Abstract

The hemoflagellate protozoan, Trypanosoma cruzi, mainly transmitted by triatomine insects through blood transfusion or from mother-to-child, causes Chagas' disease. This is a serious parasitic disease that occurs in Latin America, with considerable social and economic impact. Nifurtimox and benznidazole, drugs indicated for treating infected persons, are effective in the acute phase, but poorly effective during the chronic phase. Therefore, it is extremely urgent to find innovative chemotherapeutic agents and/or effective vaccines. Since piplartine has several biological activities, including trypanocidal activity, the present study aimed to evaluate it on two T. cruzi strains proteome. Considerable changes in the expression of some important enzymes involved in parasite protection against oxidative stress, such as tryparedoxin peroxidase (TXNPx) and methionine sulfoxide reductase (MSR) was observed in both strains. These findings suggest that blocking the expression of the two enzymes could be potential targets for therapeutic studies. (C) 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. (AU)

• FAPESP's process: 11/24017-4 - Study of selenium metabolism in primitive eukaryotes
• Grantee: Marco Túlio Alves da Silva
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 07/02076-3 - Tripanocidal activity evaluation of crude extract and fractions of Piperaceae plants
• Grantee: Regina Maria Barretto Cicarelli
• Support Opportunities: Regular Research Grants